{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.9"}]}],"title":"Non-Responders"},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.1"}]}],"title":"ACR 30 Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.1"}]}],"title":"ACR 50 Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.6"}]}],"title":"ACR 70 Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.4"}]}],"title":"ACR 90 Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.3"}]}],"title":"ACR 100 Response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"175"}],"units":"Participants"}],"description":"Adapted ACR Pediatric 30/50/70/90/100 criteria are defined as meeting all of the following:\n\n* improvement from baseline of ≥ 30%, ≥ 50%, ≥ 70%, ≥ 90%, or 100%, in at least 3 of the first 6 response variables\n\n  1. Physician's global assessment of disease activity\n  2. CHAQ-patient's overall well-being\n  3. CHAQ-Functional ability\n  4. \\# of joints with active arthritis\n  5. \\# of joints with limitation of motion\n  6. C-Reactive Protein.\n* no intermittent fever in the preceding week\n* no more than one of the first 6 response variables worsening by more than 30%","groups":[{"description":"In Part I participants received open label 4 mg/kg canakinumab subcutaneous injection every 4 weeks for up to 32 weeks. For the first 8 weeks Part Ia (4 weeks) and Ib (4 weeks) patients maintained a stable oral steroid dose (prednisone or equivalent) followed by Ic an up to 20 week steroid tapering period and then Id a 4 week stable steroid dose period. Participants were then randomized to receive either 4 mg/kg canakinumab subcutaneous injection or Placebo comparator in Part II and remained on the stable oral steroid dose for 24 weeks. At 24 weeks in Part II participants with a \\>0.2 mg/kg and ≤ 0.5 mg/kg and no flare could restart steroid tapering. If the steroid dose was ≤ 0.2 mg/kg participants continued to maintain their current dose for the remainder of Part II.","id":"OG000","title":"Canakinumab"}],"paramType":"NUMBER","populationDescription":"Participants from the full analysis set with an assessment at the given time-point.","reportingStatus":"POSTED","timeFrame":"Baseline, 32 Weeks","title":"Part I: Percentage of Participants With Minimum American College of Rheumatology (ACR) 30/50/70/90/100 at the End of Part I","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}